TaiRx, Inc. (TPEX: 6580)

Market Cap	4.04B
Revenue (ttm)	5.32M
Net Income (ttm)	-183.76M
Shares Out	110.56M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	284,528
Open	37.20
Previous Close	37.15
Day's Range	35.60 - 37.45
52-Week Range	23.20 - 44.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About TaiRx

TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2023, TaiRx's revenue was 5.08 million, a decrease of -26.59% compared to the previous year's 6.92 million. Losses were -212.29 million, 0.34% more than in 2022.